No Data
No Data
Aohua Endoscopy (688212): Short-term bidding and tendering slowed down, continue to be bullish on the volume of AQ-300
The company's performance in the first half of 2024 met expectations, with a slower revenue growth in Q2 compared to Q1. This is mainly due to industry compliance requirements and the delay in the implementation of the policy for updating and replacing medical devices, which has caused some hospitals to postpone the purchase of medical devices.
Express News | Aohua Endoscope: Shareholder Appalachian intends to reduce its shareholding by no more than 1.42%.
AOHUA Endoscope (688212): Stable income growth, expected to accelerate in the second half of the year.
Item: The company released its 2024 interim report, with revenue of 0.354 billion yuan (+22.29%) and net income attributable to the parent company of 0.006 billion yuan (-85.13%). The non-recurring net income was -0.001 billion yuan. In Q2 2024, revenue
Express News | Star market closing review: SSE Science and Technology Innovation Board 50 Index fell 0.40%, semiconductor sector showed mixed gains and losses.
Aohua Endoscopy (688212): Performance meets expectations, equity payment expenses affect reported profit.
Investment Highlights: The company has released its 2024 interim report. In the first half of 2024, the company achieved revenue of 0.354 billion yuan (+22.3% year-on-year), net income attributable to the parent company of 5.66 million yuan (-85.1% year-on-year), and non-GAAP net income attributable to the parent company of -135 million yuan.
Express News | 558 companies were surveyed this week, with Proya Cosmetics being the most recognized.
No Data
No Data